% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hutterer:825718,
      author       = {Hutterer, M. and Galldiks, N. and Hau, P. and Langen,
                      K.-J.},
      title        = {{P}itfalls in der [18{F}]-{FET}-{PET}-{D}iagnostik von
                      {H}irntumoren},
      journal      = {Der Nuklearmediziner},
      volume       = {38},
      number       = {04},
      issn         = {0723-7065},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {FZJ-2017-00035},
      pages        = {295 - 303},
      year         = {2015},
      abstract     = {In clinical neuro-oncology structural magnetic resonance
                      imaging (MRI) is currently the investigation of choice for
                      diagnosing brain tumors. In many situations, however, the
                      capacity of MRI identifying non-enhancing tumor or
                      differentiating neoplastic tissue from unspecific
                      treatment-related changes is limited.In the last years
                      positron emission tomography (PET) using radiolabeled amino
                      acids such as O-(2-[18F]-Fluoroethyl)-L-tyrosine (FET) and
                      [11C]-methionine (MET) in combination with MRI has shown a
                      great potential for a more accurate diagnosis of gliomas.
                      The decisive advantage of amino acid PET is a tumor-specific
                      tracer uptake independent from the blood-brain-barrier
                      permeability. In the diagnostics of primary brain tumors the
                      amino acid PET is able to describe the localization, extent
                      and heterogeneity of the metabolic active tumor, which can
                      be used for improved targeting of biopsy as well as planning
                      of resection and radiotherapy by better visualization of
                      tumor margins. Furthermore, following chemo-/radiotherapy
                      amino acid PET can be used for distinguishing tumor
                      recurrence from pseudoprogression and tumor response from
                      pseudoresponse during antiangiogenic treatment.The main
                      advantage of FET compared to MET is the longer half-life of
                      the [18F]-label, which allows a distribution on a wide
                      clinical scale. In addition, FET uptake appears to be more
                      specific for tumor tissue, because there is a higher uptake
                      of MET in inflammatory cells and tissues.Due to the rapidly
                      growing importance and regular use of amino acid PET in many
                      neuro-oncology centers the aim of this review is to
                      highlight the “pitfalls” especially of FET PET
                      diagnostics of brain tumors. The differential diagnosis of
                      newly diagnosed solitary cerebral lesions with or without
                      (circular) contrast enhancement on MRI includes different
                      types of malignant brain tumors, as well as various benign,
                      non-neoplastic lesions such as inflammatory, ischemic,
                      hemorrhagic or traumatic lesions.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      doi          = {10.1055/s-0035-1564177},
      url          = {https://juser.fz-juelich.de/record/825718},
}